PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2...
8 insider purchases on record · latest filing 2020-10-02.
Insiders have also filed 180 sale transactions at PMVP.